Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 649

1.

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.

Asche CV, Hippler SE, Eurich DT.

Pharmacoeconomics. 2014 Jan;32(1):15-27. doi: 10.1007/s40273-013-0117-7. Review.

PMID:
24357160
2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.

Diabetes Obes Metab. 2008 Jun;10 Suppl 1:43-55. doi: 10.1111/j.1463-1326.2008.00886.x.

PMID:
18435673
6.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

7.

Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.

Tricco AC, Antony J, Soobiah C, Hemmelgarn B, Moher D, Hutton B, Yu CH, Majumdar SR, Straus SE.

Syst Rev. 2013 Jun 28;2:47. doi: 10.1186/2046-4053-2-47.

8.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
9.

A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.

Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R.

Pharmacoeconomics. 2010;28(4):255-77. doi: 10.2165/11531590-000000000-00000. Review.

PMID:
20222752
10.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
11.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
12.

Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.

Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.

J Med Econ. 2014 Jul;17(7):499-507. doi: 10.3111/13696998.2014.912986. Epub 2014 Apr 23.

PMID:
24708176
13.

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P.

Clin Drug Investig. 2012 Mar 1;32(3):189-202. doi: 10.2165/11597060-000000000-00000.

PMID:
22292415
14.

Cost effectiveness of liraglutide in type II diabetes: a systematic review.

Zueger PM, Schultz NM, Lee TA.

Pharmacoeconomics. 2014 Nov;32(11):1079-91. doi: 10.1007/s40273-014-0192-4. Review.

PMID:
25052903
15.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
16.

The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.

Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH.

J Manag Care Spec Pharm. 2014 Sep;20(9):968-84.

17.

The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the future.

Tucker DM, Palmer AJ.

Prim Care Diabetes. 2011 Apr;5(1):9-17. doi: 10.1016/j.pcd.2010.10.001. Epub 2010 Nov 10. Review.

PMID:
21071296
18.

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.

Tunis SL, Sauriol L, Minshall ME.

Appl Health Econ Health Policy. 2010;8(4):267-80. doi: 10.2165/11535380-000000000-00000.

PMID:
20578781
19.

Screening for type 2 diabetes: literature review and economic modelling.

Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.

20.

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.

J Med Econ. 2012;15(4):654-63. doi: 10.3111/13696998.2012.670677. Epub 2012 Mar 12.

PMID:
22369345
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk